Biotechnology company developing immuno-neurology therapies for neurodegenerative diseases.
About
Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and frontotemporal dementia. They leverage insights from human genetics, neuroscience, and immunology to create treatments that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. The company also develops a proprietary Alector Brain Carrier (ABC) platform to improve drug delivery across the blood-brain barrier.
Tags
Total Employees
151
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Alector do?
Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and frontotemporal dementia. They leverage insights from human genetics, neuroscience, and immunology to create treatments that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. The company also develops a proprietary Alector Brain Carrier (ABC) platform to improve drug delivery across the blood-brai…
How much funding has Alector raised?
Alector has raised a total of $163M in funding. The most recent round on record is Series E.
Where is Alector headquartered?
Alector is headquartered in South San Francisco, United States.
When was Alector founded?
Alector was founded in 2013.
What industry does Alector operate in?
Alector operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Neuroscience.
How many employees does Alector have?
Alector has approximately 151 people on record.
Similar Startups